# Evaluating bowel preparation tolerability in IBD: a phase 3 post-hoc comparison of mannitol and PEG-ASC

**Authors:** Gian Eugenio Tontini, Alessandro Rimondi, Flavio Caprioli, Giovanni Aldinio, Luca Pastorelli, Franco Radaelli, Cristiano Spada, Maurizio Vecchi

PMC · DOI: 10.3389/fgstr.2025.1630479 · Frontiers in Gastroenterology · 2025-08-25

## TL;DR

A new bowel preparation method using mannitol is more tolerable and faster for IBD patients compared to traditional methods.

## Contribution

The study demonstrates that oral mannitol improves patient satisfaction and reduces preparation time in IBD patients.

## Key findings

- Oral mannitol showed higher patient satisfaction with ease of use, taste, and willingness to reuse compared to PEG-ASC.
- Mannitol reduced intake duration and time to evacuation while maintaining comparable efficacy and safety.
- Same-day oral mannitol is a safe and effective alternative for bowel preparation in IBD patients.

## Abstract

Bowel preparation is a significant challenge for patients undergoing colonoscopy, especially in Inflammatory Bowel Disease (IBD) patients. Oral mannitol (OM), an ultra-low-volume, single-dose osmotic laxative with a sweet taste, could improve patient tolerability. We performed a post-hoc analysis of the phase 3, multicentre, randomized, endoscopist-blinded SATISFACTION trial to compare same-day OM versus standard split-dose 2L polyethylene glycol plus ascorbate (PEG-ASC) for bowel preparation in IBD patients. Fifty-five IBD patients (24 OM, 31 PEG-ASC) were assessed for bowel cleansing efficacy, endoscopic outcomes, safety, and patient satisfaction. OM demonstrated superior tolerability, including ease of use (88% vs. 71%), taste satisfaction (75% vs. 6%), and willingness to reuse (96% vs. 71%). OM also reduced intake duration (32 vs. 107 minutes) and time to evacuation (57 vs. 91 minutes), with comparable efficacy, cleansing quality, and safety. In conclusion, same-day OM preparation enhances satisfaction and adherence in IBD patients, offering a safe, effective alternative to standard protocols.

## Linked entities

- **Chemicals:** mannitol (PubChem CID 6251), polyethylene glycol (PubChem CID 9033), ascorbate (PubChem CID 54670067)
- **Diseases:** Inflammatory Bowel Disease (MONDO:0005265), IBD (MONDO:0005265)

## Full-text entities

- **Diseases:** IBD (MESH:D015212), PEG-ASC (MESH:C536414)
- **Chemicals:** mannitol (MESH:D008353), 2L polyethylene glycol plus ascorbate (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12952433/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12952433/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12952433/full.md

---
Source: https://tomesphere.com/paper/PMC12952433